FDA Develops Formal Procedure To Refer Misleading Communications To SEC
This article was originally published in The Pink Sheet Daily
Executive Summary
Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison between the agencies. FDA will provide "blanket" authorization to certain staff to share non-public information with SEC.
You may also be interested in...
The Omniscient Regulator: QRxPharma’s Unusual Take on FDA and Investor Calls
Investor calls routinely begin with a disclaimer that the call is being recorded. They don’t usually include a warning that “FDA is monitoring the call.” But that is how QRxPharma began a discussion of a bad news event for its MoxDuo application.
FDA Refers Several Full Disclosure, Insider Trading Violations To SEC
More than half a dozen FDA-referred cases are under investigation at the Securities & Exchange Commission, official says. FDA is “struggling” to provide SEC with full disclosure support without jeopardizing confidential proprietary information. Three of the six cases also involve insider trading.
FDA Refers Several Full Disclosure, Insider Trading Violations To SEC
More than half a dozen FDA-referred cases are under investigation at the Securities & Exchange Commission, official says. FDA is “struggling” to provide SEC with full disclosure support without jeopardizing confidential proprietary information. Three of the six cases also involve insider trading.